Physician profile
Katie E Miner
NPI 1568490928
$3,166.39
in general payments reported to CMS, 2019-2025
34 companies · $606 in 2025
The $606 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $582 · 2022: $498 · 2023: $684 · 2024: $795 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,086.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $456.76 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $409.72 | 2021-2025 | |
| Corium, LLC | $265.58 | 2021-2025 | Azstarys |
| Novo Nordisk INC | $221.70 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $171.87 | 2022-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Astrazeneca Pharmaceuticals LP | $136.26 | 2023-2025 | Airsupra, Breztri, Flumist Quadrivalent |
| Intuitive Surgical, INC. | $132.49 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $130.01 | 2021 | |
| Abbott Laboratories | $115.66 | 2021-2024 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Novartis Pharmaceuticals Corporation | $113.23 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $104.00 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $100.57 | 2023-2024 | Spravato, Xarelto |
| Lilly USA, LLC | $97.75 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $88.45 | 2021-2023 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $73.67 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $71.39 | 2021-2025 | |
| Sanofi Pasteur INC. | $67.68 | 2023-2025 | |
| Ironshore Pharmaceuticals INC. | $57.06 | 2022-2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $39.71 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $39.26 | 2022-2023 | Quviviq |
| Neos Therapeutics, LP | $35.74 | 2021-2022 | |
| Neurelis, INC. | $35.40 | 2021-2023 | Valtoco |
| Verrica Pharmaceuticals INC. | $23.29 | 2024 | Ycanth |
| Corcept Therapeutics | $20.06 | 2025 | Korlym |
| Soleno Therapeutics, INC. | $18.13 | 2025 | Vykat Xr |
| Shield Therapeutics INC | $17.15 | 2024 | |
| Seqirus USA INC | $17.09 | 2025 | Fluad, Flucelvax |
| Esperion Therapeutics, INC. | $16.81 | 2021 | |
| Amgen INC. | $16.80 | 2024 | Repatha, Otezla |
| Horizon Therapeutics Plc | $15.95 | 2021 | |
| Exact Sciences Corporation | $15.40 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $14.37 | 2021 | |
| Genzyme Corporation | $14.23 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.15 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Miner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.